Legend Biotech Medical Affairs

#LegendNews: Early LB2102 data in solid tumors will be presented at #ASCO26. Additional data presented at @ASCO reinforce established efficacy and safety profile in #MultipleMyeloma. Come find us at ASCO Booth #21955 to learn more and read more at: bit.ly/4f16QCG

Just published in Clinical Lymphoma, Myeloma and Leukemia: Non-ICANS Neurologic Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With a BCMA #CART Read more: bit.ly/49Vp7O6

Thank you to those who joined us at @oncologynursing society #ONSCongress 2026 and visited our posters. We look forward to continuing the excitement at #ASCO26 #mmsm #CART

At ONS (@oncologynursing society), we’re presenting four posters this year and look forward to sharing our latest data with you.

Advancing #PatientCare is a team effort. This week at #ONS2026, the Legend team is connecting with #Oncology nurses and care teams to share perspectives, learn from each other, and support the delivery of advanced therapies. Stop by and visit our booth #1103 to learn more.

Find us at the 51st Annual @oncologynursing society #ONSCongress May 13-17, 2026 and poster presentations on May 14th.

First author: Peter Forsberg (@ForsbergMD )

Published in Blood Advances: Steroid prophylaxis for excessive lymphocyte expansion after BCMA #CART in #MultipleMyeloma Read more: bit.ly/41ZXHlZ

How is MRD shaping your approach to patient care in your practice? #MultipleMyeloma #MRD #mmsm

The Myeloma Cure Summit brought together leading experts, researchers, and advocates in the field of multiple myeloma. How might this proposed definition influence future treatment strategies and long-term management in multiple myeloma? @Myeloma_Society #MultipleMyeloma #MRD #mmsm

#LegendNews: Research highlighting our investigational solid tumor CAR-T and continued evidence generation in multiple myeloma from our #CellTherapy portfolio will be presented at @ASCO. Attending #ASCO26? Visit booth #29155 to say hello! #ASCO26 #Biotech #CancerResearch

Authors: Binod Dhakal (@bhemato) Moffitt Cancer Center (@MoffittNews) Larry Anderson (@Ldandersonjr)

Just published in Advances in Therapy: Real-World Evaluation of Efficacy and Outcomes in relapsed/refractory Multiple Myeloma with BCMA #CART #mmsm Read more: bit.ly/4s8L4zL

Explore our website here: bit.ly/4dqGnh4 #Hematology #MultipleMyeloma #mmsm

What would you say to someone who’s just been diagnosed? What can you share to remind them we are #MoreThanMyeloma? Spread hope. Share with us below. Thank you to @LegendBiotech @LegendUSMA for helping us spread myeloma awareness.

Who made you feel like you were #MoreThanMyeloma? Tag them below to thank them. ❤️#MyelomaActionMonth Special thanks to @LegendBiotech and @LegendUSMA for helping us amplify myeloma voices.

Myeloma is the 2nd most common blood cancer worldwide, but we are more than myeloma. Share what makes you #MoreThanMyeloma below! We thank Legend Biotech for helping us spread the facts. @LegendBiotech @LegendUSMA

March is #MyelomaActionMonth—a time to raise awareness and support myeloma patients and the broader community. We’re proud to collaborate with the International Myeloma Foundation (@IMFmyeloma) to amplify education and understanding. Join us in sharing why we’re #MoreThanMyeloma.

Our VP & Head of Early-Stage Drug Dev, Dong Geng, will participate in a panel on in vivo cell therapy Feb. 11 @ 1:20 p.m. at #IO360Summit. 📍 Track 2: Cell Therapy Plenary 🎤 In Vivo Cell Therapy: Rewriting the Rules of Cell-Based Treatment io360summit.com